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Postoperative infections are a major concern in patients that receive implants. These infections generally occur in areas with poor
blood flow and pathogens do not always respond to antibiotic treatment. With the latest developments in nanotechnology, the
incorporation of antibiotics into prosthetic implants may soon become a standard procedure. The success will, however, depend
on the ability to control the release of antibiotics at concentrations high enough to prevent the development of antibiotic-resistant
strains. Through additive manufacturing, antibiotics can be incorporated into cementless femoral stems to produce prosthetic
devices with antimicrobial properties. With the emerging increase in resistance to antibiotics, the incorporation of antimicrobial
compounds other than antibiotics, preferably drugs with a broader spectrum of antimicrobial activity, will have to be explored.This
review highlights the microorganisms associated with total hip arthroplasty (THA), discusses the advantages and disadvantages of
the latest materials used in hip implants, compares different antimicrobial agents that could be incorporated, and addresses novel
ideas for future research.
1. Introduction
The increased use of cementless femoral components in THA
[1], combined with the increased occurrence of THA [2],
advocates a significant and growing market for these devices.
Most cementless femoral stems are produced from wrought
titanium alloys [3], by using conventional manufacturing
processes that include rolling, forging, machining, surface
modification, finishing, cleaning, and sterilisation (Figure 1).
Metal additive manufacturing (AM) is not used in any of
the current commercial cementless hip stem manufacturing
processes.
Proximal surfaces of titanium alloy femoral stems are
often coatedwith plasma spraying to provide a porous surface
for bone ingrowth (osseointegration, Figure 2(a)). Although
bone ongrowth (Figure 2(b)) also facilitates fixation on a
roughened, nonporous surface, it provides less tensile sup-
port than bone ingrowth [4].
Clinically approved first-generation wrought titanium
alloys have crystal structures consisting of a combination of
𝛼-phase (hexagonal close packed) and 𝛽-phase (body centred
and cubic) orientations [4]. Second-generation titanium alloy
consists mostly of a 𝛽-phase microstructure with lower
elastic moduli, compared to first-generation titanium and
cobalt alloys or stainless steel and reduces stress shielding,
a phenomenon that occurs due to a mismatch between the
elastic modulus of bone and implant material [5]. Of all
alloys, titanium is the most used one due to its excellent
biocompatibility, resistance to corrosion, high strength, and
ductility [4, 6].
Concerns regarding the release of aluminium ions from
titanium alloys such as Ti-6Al-4V have been raised. Alu-
minium has been correlated to the onset of diseases such
as Alzheimer’s and cytotoxicity has been reported from
excessive concentrations of vanadium [7, 8]. These concerns
have been mitigated by developing diamond-like carbon
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Figure 1: Simplified process chain for titanium alloy cementless femoral stems (adapted from [19]).
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Figure 2: Schematic representation showing the difference between bone ingrowth (a) and bone ongrowth (b).
(DLC) film that prevents the release of elemental ions from
alloys [9].
A serious concern regarding THA devices is the increas-
ing trend in revisions due to infection [3, 10]. According to
Kurtz et al. [10], the number of THA infections in the United
States of America alone may exceed 16000 by 2020, with an
estimated treatment cost of $527.9 million. With a current
infection rate of approximately 1% for primary THA, failure
to reduce the risk of infection will only lead to increased
infection rates during revision surgeries. Furthermore, the
burden regarding treatment costs associated with infection
will continue to increase. Considering the above, combined
with the morbidity and psychological strain put on the
patient, it is clear that infection of THA is still a serious issue
inhibiting the success of the procedure and the quality of life
of many patients.
Selective laser melting (SLM) and electron beam melting
(EBM) are powder bed fusion AM processes, during which
three-dimensional (3D) parts are formed in a layer-by-layer
fashion.This enables the design andmanufacturing of a range
of products with unique features that were previously difficult
or near impossible to assemble. The latest developments in
AM triggered a renewed interest in the use of AM technology,
especially in the design and production of medical implants
with enhanced performance and novel functionalities [11,
12]. The novelty, we believe, lies in the ability to administer
multiple dosages of an antimicrobial drug in situ, from the
implant [13, 14]. By administering the drug directly to the site
of infection, postoperative surgery and removal and cleaning
of the prostheses may be avoided. If refined, this technology
could replace many of the current once-off drug release
devices that are either coated with antimicrobial compounds
or modified with the incorporation of acrylic drug-loaded
bone cements.
Implants produced with AM are used in specific cases
to reduce stiffness and patient-specific geometries [15–18]. A
cementless hip stem with enhancements such as a built-in
drug delivery system requires the design of a new process
chain. In this paper the focus falls on the application of AM in
the design of cementless hip stems with novel drug delivery
properties.
2. Infection
Infections acquired from implants are difficult to treat.
Antibiotics administered, whether orally or intravenously, do
not always reach the implant due to restricted blood flow
[21]. The surface of implants, on the other hand, is rapidly
coveredwith proteins and glycoproteins produced by the host
[22]. This results in a “conditioned surface” that supports
adhesion of bacteria [23]. Once adhered, the bacteria secrete
polysaccharides and formbiofilms to protect themselves from
antibiotics. Destruction of a biofilm is extremely difficult,
as shown in the treatment of Pseudomonas aeruginosa and
Staphylococcus aureus biofilms [24, 25]. In both cases the level
of antibiotics required for treatment is much higher than the
minimum inhibitory concentration (MIC), which is not a
practical solution. In severe cases, often seen with prosthetic
joints, the only treatment options available include debride-
ment [26], one- or two-stage arthroplasty [27], resection
arthroplasty [28], removal of the implant [29], or amputation
of the limb [30]. Recent reports highlight the increased
risk and occurrence of mortality rates associated with deep
chronic infection [30, 31]. Pathogens isolated from prosthetic
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Figure 3: A total hip replacement femoral stem concept with
internal channels (adapted from [20]).
joint infections (PJIs) after THA and total knee arthroplasty
(TKA) are listed in Table 1.
Treatment of infected femoral stems remains an area of
debate [32]. The choice between procedures depends on the
type of infection, time laps after surgery, damage to tissue
and bone, condition of the implant, andmiscellaneous factors
which are situation specific [27]. One option to prevent the
formation of bacterial biofilms is to use antibiotic-loaded
bone cement (ALBC, Table 2). Although the method is well
established and is an accepted practice, concerns about
the development of antibiotic-resistant bacteria, due to the
elution of antibiotics at levels below MIC, have been raised
[33]. This has prompted investigation into incorporation of
alternative antimicrobial compounds into bone cement. van
Staden et al. [34] incorporated nisin, a lantibiotic produced
by Lactococcus lactis subsp. lactis, into bone cement and
succeeded to control the growth of S. aureus in vivo in a
mouse model. Campoccia et al. [14] showed that implants
coated with silver nanoparticles killed most bacteria within
the first few days after surgery and the implant retained
its antimicrobial properties for 30 days, with no significant
decline in activity.
The latest development is cementless fixation of implants
and the elution of antimicrobial compounds from within
femoral stems [13]. However, conventional manufacturing
processes do not allow for intricate geometries and features
of custom-designed hip implants [35]. In a recent study
titanium alloy cubes with a novel drug delivery design were
constructed from Ti6Al4V ELI (Extra Low Interstitial) pow-
der with LaserCUSING (an AM process) with vancomycin
incorporated in channels of the cubes. Controlled release
of vancomycin could be achieved with approximately 50%
of the vancomycin released within the first 17 h [13]. The
authors managed to sustain the delivery of vancomycin for
as long as 100 h by reinjecting the channels that were sealed
with hydrophilic polyethersulfone membranes. This study
proved that refillable implants may be a novel way to control
postoperative infections.
Femoral stems used in total hip replacement (THR)
therapy are usually manufactured from wrought material by
subtractive processes. Mueller et al. [20] used selective laser
melting (SLM) to produce a prototype femoral stem similar
to that shown in Figure 3. Although EBM (electron beam
melting) acetabular cups have been approved [36], heavy load
Table 1: Pathogens isolated from prosthetic joint infections after
total hip arthroplasty (THA) and total knee arthroplasty (TKA),
adapted from [40].
Species or group Percentage
Staphylococcus aureus 22
Polymicrobial composition 19
Coagulase-negative staphylococci (CNS) 19
Unidentified Gram-negative rods 20
Streptococcus spp. 9
Anaerobic bacteria 6
Microorganisms representing 5% and less of the
cultured species:
Enterococcus spp.
Corynebacterium spp.
Listeria monocytogenes
Mycobacterium tuberculosis
Candida albicans
Brucella suis
Geotrichum spp.
bearing prostheses, such as femoral hip stems manufactured
by AM technologies, have not been approved by the United
States Food and Drug Administration (FDA) [37] and more
extensive clinical trials will have to be performed [38].
The eventual realisation of cementless femoral stems with
functional enhancements, such as integrated drug delivery
features, could also be beneficial in the treatment of infection.
This could mobilise a patient during the interim period of a
two-stage exchange or could be used as a permanent implant
in a one-stage revision.
3. Treatment
Postoperative infection is classified as either an “early” infec-
tion that occurs within 2 months after surgery or a “delayed”
infection that occurs between 3 and 24 months after surgery
[39]. In pursuit of best practices in infection management,
Zimmerli and Ochsner [39] developed a decision making
algorithm based on time elapsed after surgery, infection type,
state of the implant and surrounding tissue, and comorbidity
factors. Regardless of the procedure used, success cannot
be guaranteed. Infection rates for revision surgeries are
typically higher than those recorded for primary arthroplasty.
Persistent infections may result in amputation or even death
[29, 30].
3.1. Early Debridement with Retention. The option of treating
a prosthetic joint infection with debridement and retention
of the implant is subdued to very strict criteria, for example,
stability of the implant, stage of infection, overall health
of the patient, and the patient’s tolerance to aggressive
antibiotic therapy, whether it is administered intravenously or
orally [41]. Despite all precautions taken into consideration,
infections caused by S. aureus remain a problem in THA and
TKA [42].
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Table 2: Commercially available, FDA-approved ALBC cements.
Product Current distributor Antibiotic Concentrationa FDA approval
Simplex P Stryker Tobramycin 1.0 g 2003
Refobacin Rb Biomet Gentamicin 0.5 g 2003
Palacos R+Gb Heraeus Medical Gentamicin 0.5 g 2003
Smartset GHV DePuy Gentamicin 1.0 g 2004
VersaBond AB Smith & Nephew Gentamicin 1.0 g 2004
Cemex Genta Exactech Gentamicin 1.0 g 2004
CMW1 DePuy Orthopedics Inc. Gentamicin 1.0 g 2005
Smartset GMV DePuy Orthopedics Inc. Gentamicin 1.0 g 2008
aPer 40 g bone cement.
bOriginally developed as one product.
3.2. One-Stage and Two-Stage Exchange Arthroplasty. In one-
and two-stage exchange arthroplasty, antibiotics are admin-
istered for a minimum of two weeks before surgery. One-
stage exchange arthroplasty is only performed if pathogens
isolated from the infected area were positively identified and
if the patient’s bone material is still healthy [43]. Two-stage
exchange arthroplasty, on the other hand, is performed on
patients with abscesses and sinus tracts [39, 44]. In both pro-
cedures the infected soft tissue is debrided and the implant,
plus accompanying bone cement if present, removed. In
one-stage exchange arthroplasty the bone is “keyed” to
form a rough surface before the addition of ALBC. The
tissue surrounding the infection site is treated with selected
antibiotics based on the identified pathogens, the implant is
fixed into place, and the wound is closed [45]. If the infection
is not eradicated, a two-stage revision is performed, in which
case the implant is removed, infectious bone and tissue are
debrided, and a temporary spacer of antibiotic-loaded bone
cement is implanted to control the infection [39]. If the
implant is fixed too solidly, it may be necessary to bivalve
the femur to remove the femoral stem [43]. The patient is
kept on antibiotics for 3 weeks to 7 months and has limited
mobility during this period [40].The second stage starts with
removal of all the antibiotic-loaded beads or bone cement
spacer material and testing for the persistence of antibiotic-
resistant bacteria [43], in which case the interim period of
antibiotic treatment is extended. The new implant, usually
composed of cemented components and an ALBC prophy-
lactic, is then inserted [43]. Once the new implant is fixed
in place, the wound is closed and the patient is monitored
extensively [39]. Buchholtz et al. [45] reported a 77% success
rate with one-stage revision. Success rates as high as 86 to
100% were reported when patients were thoroughly screened
and pretreated with the correct antibiotics [39]. Two-stage
exchange arthroplasty has a higher success rate (>90% suc-
cess) compared to one-stage exchange arthroplasty [43, 44].
3.3. Resection Arthroplasty. Resection arthroplasty is also
referred to as modified Girdlestone arthroplasty [53]. The
procedure is usually performed on patients with a high
surgical risk and not fit to be exposed to one- or two-
stage revision arthroplasty [54]. Indications for secondary
resection arthroplasty are numerous and include infection
with bacteria resistant to several antibiotics, poor condition
of surrounding soft tissue, inadequate bone stock, and overall
poor health of the patient.
The entire THR prosthesis (femoral and acetabular sec-
tions) plus bone cement (in the case of cemented THA) is
removed, and the joint space and surrounding tissue are
debrided and drained of any abscess and purulence [54].
Resection of the femur is performed at the intertrochanteric
line and acetabular osteophytes are removed [53].The wound
is then drained and closed. Ossification normally occurs
between the femur and the acetabulum [55]. The disadvan-
tage of this procedure is that the joint is stiff, leaving the
patient with considerable disability, and it is therefore only
performed as a last resort.
3.4. Prophylactic Strategies. The first 6 h postimplantation is
considered the most critical when newly implanted material
is most vulnerable to infection [60]. It is thus not surprising
that prophylactic strategies to control bacterial colonisation
on THR femoral stems receive so much attention [60,
61]. Despite many concerns raised about the emergence of
antibiotic-resistant bacteria [32, 39] and the use of ALBC in
primary cemented hip replacements, antibiotics remain the
most used prophylactic treatment in primary and revision
arthroplasties [60]. This is also the standard procedure used
in the fixation of femoral stems reintroduced in second-stage
treatments [43, 60].
Initially, antibiotics were mixed into the poly(methyl
methacrylate) (PMMA) matrix at the discretion of the
surgeon. This often led to inadequate concentrations of
antibiotics added, unpredictable elution characteristics, and
adverse effects on the mechanical properties of bone cement
[62]. Furthermore, mixing of antibiotics into PMMA did
not guarantee even distribution. The range of FDA-approved
ALBC cements currently available is listed in Table 2.
Gentamicin is usually the preferred antibiotic, as it is
active against Gram-negative and Gram-positive bacteria
[63], remains active when used in combination with other
antibiotics, such as vancomycin [33], and is stable at tem-
peratures generated during the exothermic polymerisation of
PMMA bone cement [56, 64]. Release of gentamycin from
PMMA occurs in two stages; an initial burst release, typically
within the first 24 h [62], followed by a steady sustained
release for an extensive period [65]. In some reports the
transition from burst to sustained release is described as an
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Figure 4: Cumulative release of gentamicin from PMMA (adapted
from [56]).
additional stage [62]. A generic curve showing the cumulative
release of gentamicin over time is shown in Figure 4. In an
ideal situation, the cumulative concentration of gentamicin
released should reach high levels over a short period, followed
by almost no release [66].
Lewis [62] studied the release of drugs from implants
and related them to different drug delivery mathematical
models. Some models do not account for the hydrophobic
properties of PMMA and are considered inaccurate [62].
Despite modified versions of drug release models, studies
performed with the same CMW1 gentamicin bone cement
produced more than one best fit result [66].
A serious problem with the sustained subinhibitory
levels of gentamicin release from PMMA is the provocation
of antibacterial resistance [60]. In a study by Neut et al.
[67] during which gentamicin-loaded PMMA beads were
cultured after retrieval from patients, 68% of the 28 identified
bacterial strains exhibited resistance towards gentamicin.
This further emphasizes the current need for the investiga-
tion into more efficacious drug delivery strategies and the
thorough integration of the involved processing technologies
and disciplines to gain a better understanding towards the
eventual development of such combination devices.
4. Additive Manufacturing (AM) as
Enabler Technology
Severalmethods have been proposed to prevent bacteria from
colonising cementless femoral hip stems [68]. However, most
of these methods focused on processing the external surface
of the implant. Only a few studies reported on the release
of antimicrobial compounds from metallic implants [68].
Linezolid, a synthetic antibiotic, imbedded into mesoporous
silica and then incorporated into pores of a 316L stainless steel
pin, prevented the colonization of S. aureus ATCC 29213 on
the surface of the implant [68]. This opened the possibility
of incorporating prophylactic antimicrobial compounds and
osteoinductive supplements into preformed channels of an
implant.
Most of the current literature, however, inevitably results
in once-off release strategies without the possibility to tailor
drug release after implantation. Furthermore, devices seem to
be investigated by adding functionality through postprocess-
ing operations rather than developing integrated devices with
multiple drug delivery capabilities [69]. Such products would
fall under the FDA regulatory classification of combination
devices, which have their own regulatory requirements before
clinical acceptance [70].
This creates an area for the development of novel process
chains investigating AM processes as enabler technologies.
However, in developing these process chains it is important
to identify the different roles of stakeholders, especially
as these process chains would encompass interdisciplinary
communication [71]. Involved parties need to understand the
fundamental perspectives across disciplines to collaboratively
achieve an efficacious design. This implies moving from a
vertical (or line) based perspective, where each party focuses
solely on their own expertise, to amore lateral based perspec-
tive, where each party understands the fundamental topics
from all the other involved disciplines to correctly translate
and incorporate them into their own subpart of the design.
Modern AM technologies are based on the paradigm
developed in the late 1980s with liquid based stereolithog-
raphy (SLA), which is considered the cornerstone of rapid
prototyping (RP) [72]. Rapid prototyping was initially used
to create nonfunctional parts. However, as new technologies
emerged, RP evolved into the manufacture of functional
parts. These layer-by-layer processes are collectively coined
AM [73]. Within these technologies, two powder bed fusion
processes, electron beam melting (EBM) and selective laser
melting (SLM), are highlighted. In contrary to subtractive
processes, in which an object is fabricated by removing of
a large volume of starting material, the AM technologies, as
the name suggests, are characterised by adding material, thus
allowing for the manufacturing of intricate geometries and
efficient use of material [58, 73].
According to Cronska¨r et al. [74], the production cost
of highly customised femoral hip stems can be reduced by
35% if AM (electron beam melting, EBM) is used with
sufficiently large batch sizes, as a collection of parts with
different geometries can be built simultaneously. In another
study, Dehoff et al. [75] calculated a 50% cost reduction in the
manufacturing of a thin-walled aerospace bracket using AM
with appropriate processing conditions. From studies such
as these, it is clear that AM technology poses an attractive
alternative for manufacturing of new generation drug/device
combination hip implants. Metal AM processes such as EBM
and SLMcan therefore play an important role as enabler tech-
nology within the process chains of next generation implants.
In general, the AM process consists of (i) generation
of a Standard Triangulation Language (STL) file, (ii) file
verification and repair, (iii) creation of a build file, (iv)
construction of the implant, and (v) cleaning and finishing.
Digitalmanufacturing starts with CADmodelling and export
of the design in STL format. Once an STL file is generated,
it needs to be verified and defects need to be removed
[57]. Creation of the build file requires a number of steps
and concepts that have to be taken into consideration. The
first step is orientation of the implant. Due to the layer-
by-layer nature of AM, all parts will inherently have “stair
stepping” (Figure 5), except if all features are completely
vertical or horizontal [76]. This effect can be minimised by
decreasing the thickness of the layers, which in turn will
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Figure 5: Schematic representation of the stair stepping effect
obtained when slicing for finite layer approximation from the
original CAD geometry (adapted from [57]).
increase building time.The layering or “slicing” of the implant
is specified in the respective software package used during
preprocessing of the build file.
Implants are built from the bottom up, one layer at a time.
Once the implant is finished, it is removed from themachine,
support structures are removed, and the implant is cleaned.
Some implants require postprocessing such as wax or bronze
infiltration to strengthen the structure. Refining processes
are, for example, sand-blasting, grinding, or polishing, and
various heat treatments.
4.1. Electron Beam Melting. With EBM, fully functional and
nearly fully (>99%) dense metallic parts can be created
without the need for additional binder materials [77, 78].
An electron beam in a vacuum is used to melt the metal
powders layer-by-layer [58]. A simplified schematic of the
EBM process is presented in Figure 6.
The electron beam is supplied with a tungsten filament
electron gun, which emits electrons when heated in excess of
2500∘C under vacuum [77]. The nominal operating voltage
for the electron gun is 60 kV.The electron beam is positioned
and controlled by deflection coils to scan andmelt the powder
on a preheated table to form layers ranging from 0.05 to
0.2mm [58, 73]. Once a layer is completely scanned, the build
table is lowered by the layer thickness and a fresh supply
of powder is deposited from the powder depots. A powder
coating blade then moves across the build table to ensure
an even spread of powder. The layer in question is again
scanned by the electron beam and the process is repeated
until all layers are formed. Postprocessing operations include
machining such as drilling ormilling and heat treatment, that
is, annealing [79] and hot isostatic pressing (HIP) [80].
4.2. Selective LaserMelting. Selective lasermelting (SLM) has
been developed more recently and involves the production
of complex three-dimensional, near net shape, metallic parts
in a layer-by-layer manner. Thermal energy, produced by a
focused fiber laser beam, selectively scans, melts, and fuses
metallic powder particles on a powder bed, creating near
full density (>99%) parts [81, 82]. Part densities as high as
99.81 ± 0.1% have been reported using SLM-processed Ti-
6Al-4V ELI [47]. A simplified schematic presentation of the
SLM process is shown in Figure 7.
The SLM process, as the name implies, uses energy
from a laser beam instead of an electron beam to fuse the
powder particles by heating it beyond melting temperatures.
Part being made
Electron gun assembly
Powder 
Electron beam
Electron beam 
focusing lens
Electron beam 
deflection coil 
Build table
Powder coating 
blade
Inert atmosphere
Figure 6: Schematic representation of the EBM process (adapted
from [58]).
A layer of powder is evenly spread across the building plate
followed by the scanning of the two-dimensional geometry
in question. The build platform then is lowered by the preset
layer thickness (typically 30 to 70𝜇m) [59] before a fresh
layer of powder is deposited and evenly spread by the coating
blade. Powder not used is recycled [48]. The build chamber
is flushed with nitrogen or argon gas to avoid oxidation
[76]. Postprocessing includes the removal of support struc-
tures, usually by mechanical means such as machining or
light chiseling. Further treatment is often necessary, that is,
by machining, to reduce roughness or a number of heat
treatments procedures aimed at relieving residual stresses,
tailoring the microstructure, and reducing porosity [48, 83].
Parts produced by SLM have a layer of partially sintered
powder particles around their surface geometries.Markwardt
et al. [84] found that osseointegration of human osteoblasts is
promoted by these surfaces.The compliance of these surfaces,
however, has not yet been tested according to international
specifications for medical implants.
5. Ti-6Al-4V ELI Powder
A significant percentage of cementless stems are made from
Ti-6Al-4V ELI powder. Grade 23 Ti-6Al-4V ELI is widely
used in the manufacturing of medical implants and devices.
5.1. Surface Texture. As-built parts produced with SLM gen-
erally have a lower surface roughness than its EBM counter-
parts. In-house measurements on SLM parts have revealed
an average of absolute values for deviations from a central
plane (𝑅
𝑎
) to be typically around 10 𝜇m while values ranging
from 15 to 22𝜇m have been reported for EBM [85]. These
surfaces have good machinability and if required, parts can
be finished to have surface roughness below 1.0 𝜇m.However,
these inherent rough surfaces have proved to promote bone
ingrowth in several investigations for both SLM and EBM
[84, 86], while the surface chemistry has also been shown
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Figure 7: Schematic representation of the SLM process (adapted from [59]).
to conform to international standards [85]. Surfaces can also
be made bioactive through postprocesses such as NaOH
and HCl soaking to enhance its osteoconductive properties
[87]. Utilisation of these as-built rough surfaces eliminates
the need of extra postprocessing operations such as plasma
spraying or grit blasting, reducing time, and waste in the
process chain, resulting in more resource efficiency.
5.2. Tensile Properties. Not all literature specifies whether Ti-
6Al-4V (grade 5) or Ti-6Al-4V ELI (grade 23), which has
reduced content percentage of interstitial impurity atoms, has
been used. In this review, only publications explicitly stating
that grade 23 powder alloy was used are discussed. This alloy
has been specifically selected for discussion on the basis of
its FDA approval for production of cementless hip stems and
its availability in powder form, conforming to international
specifications, from the respective manufacturers of laser
and electron beammelting machines. As-built titanium alloy
parts generatedwith the SLMprocess have appropriate tensile
and yield strengths but lack the necessary ductility.This is due
to the resultant microstructure of the as-built material, which
contains ametastable acicular martensitic (𝛼󸀠) structure [49].
With EBM, the as-built microstructure is dominated by an
acicular 𝛼 phase but also includes a small percentage of 𝛽
phase, yielding a brittle part. Consequently, for both of these
processes, ductility needs improvement with appropriate
postprocessing operations. Tailoring of the microstructure
by using different heat treatments can transform the SLM
𝛼
󸀠 phase to the more ductile 𝛼 + 𝛽 phase which render
these materials comparable to their wrought counterparts
[47, 52, 84, 88].
Table 3 summarizes some of these results and compares
them to the tensile properties specified in ASTM F136-
08 for wrought Ti-6V-4V ELI used in surgical implant
manufacturing [46]. By applying suitable postprocesses, such
as machining, polishing, and heat treatment strategies, the
properties can be improved significantly. Depending on
the intended application, trade-offs should be considered
between the advantages of rough surfaces for bone ingrowth
and required mechanical properties. Considering the above
and the values in Table 3, it can be concluded that the tensile
properties of Ti-6Al-4V ELI manufactured with SLM and
EBM with appropriate postprocesses adhere to the standard
specification as set out for the currently used wrought
counterpart. An area of concern, however, regarding parts
produced by these processes is fatigue strength.
5.3. Fatigue Strength. International standards for fatigue
strength specify that the head region and neck region of a
femoral stem have to withstand 10 million cycles of loading,
as determined according to the test described in ISO 7206-
6:1992 [89]. Characterisation of fatigue properties of SLM
parts is, however, based on standardised specimen geometries
and does not necessarily account for unusual geometries [83].
Properties from standardised specimens may vary to that
of unconventional parts, due to the random distribution of
porosity which is an inherent issue in the current state of
the SLMmanufacturing process [48, 83]. Techniques such as
preheating of the powder bed may improve SLM processes
[90]. Hot isostatic pressing (HIP) reduces porosity to almost
negligible levels and is reported to increase fatigue strength
[83]. Although promising results have been published [74],
inconsistencies, likely due to randomporosity due to subopti-
mal processing parameters [91], are preventing the successful
commercialization of load-bearing devices.
6. Summary
6.1. Conclusions. Postoperative infections of THAs still
remain a devastating complication. The high financial bur-
den, morbidity, and psychological affliction further empha-
size the need for continual improvement and evaluation
of prevention and treatment alternatives. While promising
results have been reported in recent literature, some issues
still remain, allowing room for improvement, for example,
the delivery of multiple doses through implants instead of
employing once-off delivery strategies. With the evolution
of AM technologies such as SLM and EBM which allow
the direct manufacture of near net shape metallic parts,
drug delivery functionality can be designed into cementless
femoral stems to attend to aforementioned shortcomings.
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Table 3: SLM and EBM as-built (heat treated) tensile properties in comparison to ASTM F136-08.
Process/standard Machine Tensile strength[MPa]
Yield strength
[MPa] % elongation Heat treatment Reference
ASTM F136-08a N/A 860 795 10 (minimum) — [46]
ASTM F136-08b N/A 825 760 8 (minimum) — [46]
SLM Concept laser M2 1211–1262(950–1060)
1100–1150
(890–1030) 7.2–9 (6.5–11.7)
Recrystallisation
annealing [47]
SLM Concept laser M2 ±1200 (1000–1100) >1000 (925–1000) <10 (12–18) HIP [48]
SLM LM-Q (custom built) 1267 ± 5 (948 ± 27) 1110 ± 9(899 ± 27) 7.28 ± 1.12 (13.59 ± 0.32) Beta annealing [49]
EBM Arcam A2 928 N/A 3% — [50]
EBM Arcam S400 928 ± 9.8 869 ± 7.2 9.9 ± 1.7 — [51]c
EBM Arcamd 904 ± 6 (902 ± 8.7) 802 ± 7.9(807 ± 8.4) 13.8 ± 0.9 (14.8 ± 0.5) HIP [52]
aSpecified for diameters of 4.75 to under 44.45mm.
bSpecified for diameters of 44.45 to under 63.50mm.
cSamples were machined for a smooth surface but no heat treatment was done.
dMachine not specified, and although not explicitly stated by the authors, it is suspected that as-built samples were first machined considering the elongation.
This however brings new challenges pertaining to the devel-
opment of such implants, which fall under the classification
of combination devices. For example, intraosseous delivered
drugs may behave differently than that of intravenous or
orally administered formulations. Bolus injections of 250
and 500mg vancomycin, intraosseously, have been admin-
istered successfully without eliciting toxic side-effects [92]
while, in a different study, no significant difference between
intraosseous and intravenous administration of morphine
sulphate was observed [93]. Drug delivery dosages can also
be a combination of four formulations, diffusing at a defined
rate while the reservoir is continuously replenished over six
weeks by microsphere formulations, as described by Wang
et al. [94]. Successful incorporation of such formulations
will eliminate the need for administering multiple dosages,
further enhancing the functionality of such implants. Such
functional enhancements also bridge the once-off, single
formulation release of current strategies to enable in situ
administration of different drugs formulated according to
release requirements.
6.2. Future Work. Various research avenues flow from the
development of such a device. From a pharmaceutical per-
spective it is important that each new drug formulation be
assessed to determine its optimal administration route and
concentration, as this can differ depending on the biochem-
ical, pharmacodynamic, and pharmacokinetic properties of
each drug. The release mechanism as well as the internal
implant design is directly affected by this.
Consequently, an iterative design process with simulation
of mechanical properties should ensue to establish a feasible
internal channel and reservoir design that strives tominimize
the detrimental effect of material removal from the bulk
structure. As such devices do not exist, there is a requirement
for the development and evaluation of new process chains
in order to demonstrate the most efficient manufacturing
method for a given design. Such chains should be evaluated
specifically for resource efficiency during small batch as well
as its capability for series production.
It is evident that such an endeavour is inherentlymultidis-
ciplinary in nature. Therefore, procedures for the integration
of stakeholders across different disciplines into development
teams which can provide a more comprehensive basis of
knowledge inserts from various perspectives are important.
A knowledge platform for effective collaborationwould aid in
elucidating interactions between aspects regarding involved
disciplines which otherwise are often overlooked.
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